ProKidney Corp. (NASDAQ:PROK) Receives Average Rating of “Hold” from Analysts

ProKidney Corp. (NASDAQ:PROK) has received a consensus recommendation of “Hold” from the seven ratings firms that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $7.40.

Several equities analysts have issued reports on the company. HC Wainwright initiated coverage on ProKidney in a research report on Tuesday, December 16th. They issued a “buy” rating and a $12.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProKidney in a research note on Thursday, January 22nd.

ProKidney Stock Performance

PROK opened at $1.98 on Friday. ProKidney has a twelve month low of $0.46 and a twelve month high of $7.13. The firm has a market cap of $595.64 million, a price-to-earnings ratio of -3.60 and a beta of 1.79. The firm’s 50-day simple moving average is $2.27 and its 200-day simple moving average is $2.57.

ProKidney (NASDAQ:PROK) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.12) earnings per share for the quarter, hitting the consensus estimate of ($0.12). The firm had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.04 million. As a group, sell-side analysts anticipate that ProKidney will post -0.57 EPS for the current fiscal year.

Insider Activity at ProKidney

In other news, Director Brian Jg Pereira sold 502,136 shares of ProKidney stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $2.37, for a total value of $1,190,062.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 41.49% of the company’s stock.

Institutional Trading of ProKidney

Several institutional investors and hedge funds have recently added to or reduced their stakes in PROK. Zullo Investment Group Inc. bought a new position in shares of ProKidney in the 3rd quarter valued at about $28,000. Catalyst Funds Management Pty Ltd acquired a new stake in ProKidney during the 2nd quarter worth $36,000. AQR Capital Management LLC lifted its stake in shares of ProKidney by 106.4% in the 1st quarter. AQR Capital Management LLC now owns 52,570 shares of the company’s stock valued at $46,000 after purchasing an additional 27,098 shares during the period. FNY Investment Advisers LLC boosted its position in shares of ProKidney by 590,620.0% in the 4th quarter. FNY Investment Advisers LLC now owns 59,052 shares of the company’s stock worth $132,000 after purchasing an additional 59,062 shares during the last quarter. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of ProKidney during the third quarter worth $158,000. 51.59% of the stock is owned by institutional investors.

About ProKidney

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.